Mayo Clinic Proceedings

Our medical research library holds 6 studies published in Mayo Clinic Proceedings (1985–2021). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 4 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it. For 1 study PubMed has no abstract for, we give the abstract printed in the article or, where there is none, a summary we wrote from it, each labeled as such.

About the journal

• Publisher: [Oxford, England] :
• Published: 1964 to the present, England
• Language: English
• ISSN: 0025-6196 (print), 1942-5546 (electronic)
• Continues: Mayo Clinic. Proceedings of the Staff Meetings of the Mayo Clinic
• Its record in the NLM Catalog

2020s

• Corneal Epitheliopathy Associated With Antibody-Drug Conjugates. S.V. Patel, L.A. Dalvin. 2021;96(7):2001-2002. Case report PubMed · Publisher

  Summary

  This illustrated report (a Medical Image article) described corneal epithelial changes in 3 patients receiving different antibody-drug conjugate (ADC) therapies that inhibit tubulin assembly. The authors were from the Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. One patient received anetumab ravtansine for malignant pleural mesothelioma. One received ado-trastuzumab emtansine for human epidermal growth factor receptor-positive ductal carcinoma of the breast. One received belantamab mafodotin for refractory myeloma. The findings were shown in clinical photographs, including retroillumination photography and fluorescein staining. The authors explained that some ADCs cause 2 types of corneal epitheliopathy that can coexist and cause symptoms. Microcystic intraepithelial changes presumably represent apoptotic epithelial cells caused by payload toxicity to corneal epithelial stem cells at the peripheral limbus. These changes began in a peripheral annular distribution and gradually encroached on the center of the cornea. Superficial punctate epitheliopathy, detected by fluorescein staining, results from tear film dysfunction and rarely may proceed to corneal ulceration. Both types can cause blurred vision and photophobia, and the superficial type can cause ocular surface discomfort. According to the authors, symptoms and signs gradually resolve after treatment is withheld or discontinued, and the microcystic changes are replaced by regenerated normal epithelium. The authors noted that these findings are most frequent with belantamab mafodotin, which requires an ophthalmic examination before every treatment. They concluded that patients with ocular symptoms receiving similar ADCs should be assessed for corneal changes.

  PubMed has no abstract for this study, and the article doesn't print one. We wrote this summary from the full article with the help of AI. It is not the authors' wording.

2010s

• Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. A.S. Mansfield, T. Peikert, N.J. Vogelzang, et al. 2018;93(8):1026-1033. Randomized trial PubMed · Publisher · Free full text

  Abstract

  Objective: To understand the relationship between response and survival in malignant pleural mesothelioma (MPM).

  Patients And Methods: The original clinical trial was conducted from April 1999 through March 2001. Patients with epithelioid MPM (n=305) were categorized using modified pleural Response Evaluation Criteria in Solid Tumors by whether they responded to treatment. Median progression-free survival (PFS) and overall survival (OS) were estimated and hazard ratios for responders and nonresponders were estimated and compared using the log-rank test. Multivariable Cox proportional hazards models were used to adjust for baseline prognostic factors.

  Results: Patients who responded to frontline therapy had a significantly longer OS (hazard ratio, 0.34; 95% CI, 0.24-0.49; median, 20.6 months; 95% CI, 15.3 months to not reached) than did those who did not respond (median, 9.4 months; 95% CI, 8.1-11.0 months) (P<.001). Similarly, responders had a significantly longer PFS (hazard ratio, 0.50; 95% CI, 0.39-0.64; median, 7.8 months; 95% CI, 6.5-8.5 months) than did nonresponders (median, 3.7 months; 95% CI, 2.9-4.3 months) (P<.001). These results were confirmed when adjusting for baseline prognostic factors. We also observed a survival benefit associated with disease stabilization in MPM.

  Conclusion: Our findings indicate that reduction in tumor burden or disease stabilization determined using modified pleural Response Evaluation Criteria in Solid Tumors is strongly associated with OS and PFS in epithelioid MPM.

  Copyright © 2018 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

• Malignant Pleural Mesothelioma. M.C. Bois, H.E. Lee, L.A. Erickson. 2016;91(7):e103-4. PubMed · Publisher

1990s

• Occupational lung cancer. P.L. Whitesell, C.W. Drage. 1993;68(2):183-8. Review PubMed · Publisher

  Abstract

  Exposure to certain industrial agents has been thought to have carcinogenic potential, both for employees who work closely with such agents and for the general population that comes in contact with them. Although case reports, laboratory studies, and epidemiologic analyses help to determine the carcinogenicity of implicated agents, each of these types of investigation has limitations and deficiencies in distinguishing causal from noncausal associations. Asbestos has been linked with bronchogenic carcinoma, but several controversial factors--the degree of risk relative to exposure dose, the synergistic effect of cocarcinogens, and the question of existence of a threshold dose--complicate the understanding of the magnitude of the risk for exposed persons. Several other physical and chemical agents (such as chromium, nickel, and radon) have also been associated with an increased incidence of lung cancer in epidemiologic and animal studies. As with asbestos, the specific type of the agent and exposure conditions are important in determining the degree of carcinogenicity. In studies of exposure to man-made mineral fibers, formaldehyde, and silica, the findings have been inconsistent. Because the degree of health hazard attributable to asbestos and other known and suspected lung carcinogens is controversial, a wide range of opinions exists about the importance of occupational exposures to the overall incidence of lung cancers. Nevertheless, attempting to prevent lung cancers by minimizing or eliminating exposure to carcinogens is preferable to treating existent cases.

1980s

• Malignant mesothelioma of the pleura. R.J. Pisani, T.V. Colby, D.E. Williams. 1988;63(12):1234-44. Review PubMed · Publisher

  Abstract

  Malignant mesothelioma of the pleura most commonly occurs in persons with a heavy occupational exposure to asbestos. Some patients, however, have no such history of exposure. Clinical features include initial complaints of nonpleuritic chest pain and dyspnea. The most frequent roentgenographic finding is a unilateral pleural effusion. Thrombocytosis and elevated erythrocyte sedimentation rates are common. Pleural effusions are typically exudates, are often hemorrhagic, and are usually insufficient for diagnosing mesothelioma based on cytology alone. Even pleural biopsy may not produce enough tissue to enable the pathologist to make a firm diagnosis. Thoracotomy and open biopsy will confirm the diagnosis in most cases. Pathologic distinction from metastatic adenocarcinoma may be difficult even after the use of special stains and electron microscopy. Clinical deterioration is primarily attributable to local spread of tumor. Several factors seem to predict prolonged survival: (1) epithelial histologic subtype, (2) performance score, (3) age of the patient at the time of diagnosis, and (4) absence of chest pain. Surgical treatment, chemotherapy, and irradiation, alone or in combination, have been used for malignant mesothelioma. Except for the palliative effect of irradiation, most treatment protocols have not altered the dismal median survival of approximately 11 months seen in untreated patients with malignant mesothelioma.

• Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. U.B. Prakash, H.M. Reiman. 1985;60(3):158-64. PubMed · Publisher

  Abstract

  We retrospectively studied the results from thoracenteses and needle biopsies of the pleura performed in 414 patients with pleural effusions between 1973 and 1982. The final causes of effusion were malignant disease in 281 patients (67.9%) and nonmalignant disease in 133 (32.1%). The presence of pleural malignant disease was established by cytologic study in 162 patients (57.6%), by needle biopsy in 123 (43%), and by either cytologic analysis or biopsy in 182 (64.7%). In only 7.1% of the 281 patients with malignant pleural effusions did biopsy reveal malignant disease when the results of cytologic study were negative for malignant disease. Nearly half of the patients with lymphoma had lymphocytosis of the pleural fluid, but neither this finding nor the lymphocytic pleuritis noted on biopsy was diagnostic of lymphomatous involvement of the pleura. Among the patients with malignant mesothelioma, thoracotomy was necessary to confirm the diagnosis in 60.9%. In the patients with nonmalignant diseases, with the exception of six with tuberculous pleurisy, pleural biopsy was nondiagnostic even though the causes of pleural effusion were apparent from the clinical features. The causes of pleural effusion remained unknown in 82 patients (19.8%). Pleural biopsy failed to provide adequate tissue in 55 patients (13.3%). This study shows that cytologic analysis has a higher sensitivity (P less than 0.001) than needle biopsy for diagnosing malignant pleural effusions. The value of needle biopsy is limited in establishing the cause of pleural effusion that results from either malignant or nonmalignant disease, with the exception of tuberculous pleurisy.(ABSTRACT TRUNCATED AT 250 WORDS)

Browse every journal in the library or the library by type of article, or return to medical research.